Analysts Set The Beauty Health Company (NASDAQ:SKIN) Target Price at $2.81

Shares of The Beauty Health Company (NASDAQ:SKIN) have been given a consensus recommendation of “Hold” by the five research firms that are currently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $2.8125.

SKIN has been the topic of several research reports. Stifel Nicolaus raised their target price on shares of Beauty Health from $3.00 to $4.00 and gave the stock a “hold” rating in a report on Friday, August 1st. TD Cowen raised their price target on Beauty Health from $2.00 to $2.50 and gave the stock a “hold” rating in a research note on Monday. Roth Capital began coverage on Beauty Health in a research report on Friday, September 19th. They issued a “buy” rating and a $3.50 target price on the stock. Wall Street Zen raised Beauty Health from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Finally, Cowen reissued a “hold” rating on shares of Beauty Health in a research report on Monday.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Soleus Capital Management L.P. purchased a new position in shares of Beauty Health during the 2nd quarter worth $1,910,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Beauty Health by 40.8% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,570 shares of the company’s stock valued at $120,000 after purchasing an additional 18,128 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Beauty Health by 33.5% during the second quarter. The Manufacturers Life Insurance Company now owns 41,488 shares of the company’s stock valued at $79,000 after purchasing an additional 10,410 shares in the last quarter. Mirabella Financial Services LLP lifted its position in Beauty Health by 5.0% during the second quarter. Mirabella Financial Services LLP now owns 12,861,549 shares of the company’s stock valued at $24,566,000 after purchasing an additional 614,602 shares in the last quarter. Finally, Invesco Ltd. lifted its position in Beauty Health by 6.6% during the second quarter. Invesco Ltd. now owns 98,427 shares of the company’s stock valued at $188,000 after purchasing an additional 6,059 shares in the last quarter. Hedge funds and other institutional investors own 93.26% of the company’s stock.

Beauty Health Trading Down 5.4%

Beauty Health stock opened at $1.94 on Tuesday. The company has a debt-to-equity ratio of 4.91, a current ratio of 5.15 and a quick ratio of 4.15. Beauty Health has a one year low of $0.78 and a one year high of $2.69. The stock has a market capitalization of $246.03 million, a PE ratio of -6.93 and a beta of 1.23. The business’s fifty day moving average is $2.04 and its 200 day moving average is $1.67.

Beauty Health (NASDAQ:SKIN) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.09. The firm had revenue of $78.20 million for the quarter, compared to the consensus estimate of $74.67 million. Beauty Health had a negative net margin of 6.13% and a negative return on equity of 32.82%. Beauty Health has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, sell-side analysts predict that Beauty Health will post -0.25 EPS for the current year.

About Beauty Health

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.